Tscan Therapeutics Inc (TCRX) 13F Holdings Overview (Q2 2026)

TCRX ranks #5705 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

TCRX is a top-conviction position for DC Funds, LP — at 49.3% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Two Sigma Investments, LP has added to its TCRX position for two straight quarters, increasing it by $1.3M to reach $1.9M today.

Susquehanna International Group, LLP has trimmed its TCRX position for two straight quarters, cutting it by $193.0K while still holding $23.2K.

TCRX is down 3.3% today, but institutions show net buying of $620.2M this quarter — a divergence between today's price move and the underlying institutional flow.

TCRX reported a net loss of $117.7M over the trailing twelve months.

• Not yet profitable — net loss of $117.7M over the trailing twelve months
• Revenue grew 2.2% year over year
• Net income improved year over year, from -$136.8M to -$117.7M
• Operating cash flow was negative, using $135.3M in cash
• Current ratio of 8.41x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.86x equity — within a conventional range